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Abstract
Background. Randomized, controlled comparisons
between home haemodialysis (HHD) and centre
haemodialysis (CHD) have not been performed to
date. Reported survival beneﬁts of HHD as compared
with CHD from uncontrolled studies have been
attributed largely to patient selection.
Methods. In order to minimize a selection bias, we have
compared the outcome of our HHD and CHD patients
with a nested case-cohort study. For each patient
trained for HHD at our dialysis centre between 1970
and 1995 (n¼ 103), a corresponding match was
searched from the CHD patients by retrospective
chart analysis. The pairs were matched for sex, age
(±5 years), time of dialysis therapy onset (±2 years)
and renal disease category. For 58 of the 103 HHD
patients, a corresponding matched CHD patient was
identiﬁed. Both treatment groups had the same mean
age (50±13 years) at dialysis onset and were compar-
able with respect to the Khan comorbidity index,
prevalence and duration of hypertension, smoking
habits, history of myocardial infarction, stroke and
peripheral vascular disease. In both groups, 50% of
the patients were transplanted during the observation
period.
Results. HHD patients were hospitalized less often
and tended to have fewer operations as compared with
CHD patients. Survival was signiﬁcantly longer in
HHD as compared with CHD. Five, 10 and 20 year
survival rates were 93 (n¼ 55 patients at risk), 72 (41)
and 34% (11) with HHD and 64 (38), 48 (26) and 23%
(4) with CHD, respectively. This survival difference
persisted after adjusting for predictors of mortality, i.e.
age at onset of dialysis, year of start of dialysis therapy
and Khan comorbidity index.
Conclusions. HHD offers a cheap and valuable alter-
native to CHD, with no apparent disadvantages.
Keywords: case-cohort study; home haemodialysis;
survival
Introduction
For 40 years home haemodialysis (HHD) has been
recognized as a possible alternative to renal replace-
ment therapy at a dialysis centre (CHD). HHD started
in Japan in 1961 [1,2], and became available in Boston
in 1963 [2] and 1 year later in London [2]. The ﬁrst
patient to start HHD in Switzerland did so in 1964.
He was a mountain guide who had been trained in
London [3].
Today, the predominant renal replacement therapy
modality in Switzerland is CHD. The maximum
incidence of HHD was reached in 1977 when 15% of
all the patients on dialysis started treatment by this
modality [3]. While there were still 12% of the
patients treated by HHD in 1986 [3], a steady decline
of the number of patients on HHD down to 29 patients
(<3%) (March 2003) was observed thereafter. A similar
decline in the number of patients treated with HHD
during the last years was observed in most countries. In
the United States, the incidence of HHD therapy
dropped from 40% in the early 1970s to 0.5% in 2000
[4]. Today, relevant numbers of patients treated with
HHD are reported only from Australia (17%) and New
Zealand (16%) [5].
Part of the decline in incidence numbers of HHD has
been attributed to the rapid rise of peritoneal dialysis
[2,6]. Interestingly, the use of peritoneal dialysis has
also started to diminish in many Western countries.
The current decrease of home dialysis methods is prob-
ably mainly due to socio-economics and, possibly, to
medical reasons. The end-stage renal disease (ESRD)
population became older with a higher fraction
of diabetic and polymorbid, disabled patients. In
addition, more for-proﬁt units were established,
which traditionally do not encourage HHD [2]. In
Switzerland, a further obstacle is the difﬁculty to recruit
relatives willing to assist HHD patients.
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Besides transplantation, HHD has been reported
to provide the best quality of life, most independence
and the best working rehabilitation for ESRD patients
[2]. Apart from the above-noted medical and social
beneﬁts, HHD offers a great economic advantage: in
Switzerland the annual cost of HHD is estimated as
sFr 54 000 compared with sFr 78 000 for CHD. There
have even been reports of a substantially lower
mortality with HHD compared to either CHD or
continuous ambulatory peritoneal dialysis (CAPD) [7].
Analyses of survival by modality are complicated by
non-random assignment to treatment modalities and,
further, when patients are treated with sequential
modalities. The reported differences in survival
between HHD and CHD patients have often been
attributed to selection bias [8]. HHD patients in general
differ from patients treated in medical facilities with
respect to age, race, sex and cause of ESRD, all factors
with signiﬁcant impact on survival [7,9]. In general,
HHD patients are younger, less frequently have
diabetes mellitus as a cause of ESRD, are more likely
to be white and men, and have a higher socio-economic
status and a more stable family life.
The current study compared patients on HHD with
CHD patients matched for gender, time and age at
onset of dialysis as well as for primary renal disease,
with a follow-up over 20 years. The intention was to
analyse whether the better survival rate reported with
HHD was due to haemodialysis modality.
Subjects and methods
Patient selection
All patients starting HHD at the University Hospital of Berne
between 1970 and 1995 were identiﬁed. These 103 patients
comprised all patients starting HHD in the district of Berne.
None of the other dialysis facilities in the district trained
patients for HHD during this period.
For each dialysis patient treated at home, a corresponding
match was searched from the haemodialysis patients treated
in the centre during the same period by retrospective chart
analysis. Each matched pair of patients had to have the same
sex and age (±5 years), to start haemodialysis treatment at the
same time (±2 years) and to have the same underlying cause
of renal disease causing ESRD (i.e. glomerulonephritis,
pyelonephritis, analgesic nephropathy, Polycystic kidney
disease, renal vascular disease, unknown). Patients eligible
for matching were treated by haemodialysis for 3 months
prior to any change of renal replacement therapy.
Intermittent peritoneal dialysis for 1 month was accepted.
Patients treated at any time by HHD or self-care dialysis were
excluded as possible matches for the HHD treatment group.
When more than one possible match was available for any
HHD patient, the one CHD patient who started dialysis
treatment at a time-point closest to the corresponding HHD
patient was selected.
Retrospective chart analysis of the HHD and the CHD
patients was done by two independent persons. Matching was
done prior to the data analysis of the HHD patient group and
was not changed thereafter.
The stringent matching criteria described above allowed
the selection of only 58 of the 103 HHD patients for com-
parison with a corresponding match from the CHD popula-
tion. The 58 matched HHD patients did not differ from
the total population of 103 HHD patients with respect to
marital status, sex, age, renal diagnosis, year and age at
dialysis onset, employment status and the comorbid con-
ditions mentioned below.
Data collection
Data collected included patient identiﬁers (age, sex and
marital status), renal diagnosis, information concerning year
of dialysis onset, age at dialysis onset and information
concerning last employment status. The presence or absence
of a variety of comorbid conditions before onset of dialysis
was recorded. These comorbid conditions were history of
cigarette smoking, diabetes mellitus, treatment of hyperten-
sion, myocardial infarction, cerebrovascular or peripheral
vascular disease, tuberculosis and chronic obstructive
pulmonary disease.
Follow-up data included morbidity and mortality during
the dialysis period, including operations, hospitalizations and
date of death or transplantation.
Analytical methods
Only the matched 58 pairs of patients were used for further
analysis.
Due to the number of cases, most of the data being
categorical and the non-normal distribution of the continuous
data, we chose non-parametric methods of statistical analysis.
Since this was a survey of paired data, we used the Sign test or
the Friedman two-way analysis of variance when comparing
multiple variables between cases and control.
Comorbidity was scored using the Khan comorbidity index
[10]. This index, derived from patient age and number of
comorbidities, has been shown to be appropriate to express
the prognostic impact of comorbidity on mortality risk in
patients with ERSD [10].
Survival time was deﬁned as the time from the initiation of
the ﬁrst dialysis treatment until death from any cause or the
last date of follow-up alive. Survival plots were done using the
Kaplan–Meier estimation. The initial comparison of the two
groups was performed using the log-rank test. After univari-
able analysis, possible predictive factors (treatment modality,
gender, smoking status, marital status, Khan comorbidity
index and renal disease) were entered into a multivariable Cox
proportional hazards model. Insigniﬁcant variables were
eliminated using a backward elimination procedure.
All statistical analyses were performed with the software
Systat 10 (SPSS Inc., NY, USA) on a personal computer.
Results
Basic patient characteristics of both groups are given
in Table 1. Two-thirds of both groups were male. The
majority of patients in both groups were married, but
the proportion tended to be higher in HHD than CHD
(84% vs 70%). Both populations were comparable
with respect to the proportion of smokers, history of
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myocardial infarction, cerebrovascular and peripheral
arterial disease, chronic respiratory illness, age and year
of dialysis onset.
Primary renal disease was a matching variable
and, therefore, did not differ between the two groups.
Diagnoses included in each group were glomerulo-
nephritis 18 (31%), pyelonephritis 9 (16%), analgetic
nephropathy 18 (31%), ADPKD 9 (16%) and renal
vascular disease 3 (5%). There was one patient in each
group with a renal disease of unknown origin.
Patients with relatively benign overall prognosis were
prevalent in both groups (Table 1) and no difference
with respect to the distribution of the Khan comor-
bidity index between the two groups was observed
(Table 1). There was neither a difference with respect to
the mean duration of hypertension nor to the high
percentage of patients treated for arterial hypertension
between the two groups (Table 2). Six patients treated
in-centre were hepatitis B antigen-positive as compared
with two patients treated at home (not signiﬁcant).
About half of the patients from both groups were
transplanted during follow-up (Table 2).
The same dialysis treatment parameters and time
prescriptions were used at home and in the centre.
Mean weekly treatment times were 9.5±1.9 h/week
at home and 9.4±2.6 h/week in the centre, with
2.5±0.4 and 2.3±0.5 treatments per week, respec-
tively. Estimates of urea reduction rates were avail-
able from 45 patient pairs (63±6% vs 61±7%).
About half of the patients of each group remained
employed during dialysis (Table 2). Neither the number
of employed patients nor the mean percentage of work
ability differed between the two groups (Table 2). HHD
patients tended to work more often in technical or
farming occupations, respectively, as compared with
CHD patients who more often did ofﬁce work.
CHD patients were more likely to be hospitalized,
mainly due to dialysis-related problems, such as
uraemic symptoms or volume overload (Table 3).
Furthermore, CHD patients were more often hospital-
ized for ‘social’ reasons as compared with HHD
patients. No differences were found between the two
groups with respect to hospitalizations for uncontrolled
hypertension, complications of bleeding, access opera-
tions or cardiac problems.
CHD patients had more abdominal problems
and they had a higher rate of cholecystectomies and
Table 3. Morbidity during dialysis deﬁned as event (n) per patient
HHD CHD
Hospitalizations total 6.3a 10.5
Dialysis-associated problems 1.0a 2.3
Uncontrolled hypertension 0.3 0.4
Uraemia-related 0.1a 0.8
Vascular problems 1.2b 2.0
Abdominal problems 0.3a 1.0
Gynaecological/urological 1.4 1.7
Cardiac problem 0.5 0.7
Bleeding 0.1 0.1
Social reasons 0.05b 0.5
Operations total 6.4 8.8
Parathyroidectomies 0.2a 0
Laparatomies 0.3a 0.7
Cholecystectomies 0.05 0.1
Appendectomies 0.1 0.3
Sigmoidectomies 0.02 0.1
Bleeding complications 0.09 0.05
Cataract 0.1 0.1
Gynaecological/urological 1.7 2.5
Cardiac 0.05 0.03
Vascular access 2.5 3.9
Carpal tunnel syndrome 0.3a 0.05
Data are number per patient.
aP<0.001 and bP<0.05, as compared with CHD.
Table 1. Basic patient characteristics at the start of haemodialysis
treatment
HHD CHD
n 58 58
Male (%) 39 (67%) 39 (67%)
Married (%) 55 (84%) 41 (70%)
Year of dialysis onset (SD) 1983 (6.3) 1983 (6.6)
Age at dialysis onset
(years) (SD)
50.1 (13.5) 50.6 (13.1)
Diabetes (%) 0 (0%) 1 (1.7%)
Smokers (%) 16 (27.6%) 20 (34.5%)
History of myocardial
infarction (%)
3 (5.2%) 4 (6.9%)
History of cerebrovascular
disease (%)
1 (1.7%) 3 (5.2%)
History of peripheral arterial
disease (%)
2 (3.4%) 3 (5.2%)
Tuberculosis 3 (5.2%) 4 (6.9%)
COPD (%) 7 (12.1%) 7 (12.1%)
Khan comorbidity index
Low risk 50 (86%) 43 (74%)
Medium risk 3 (5%) 10 (17%)
High risk 5 (9%) 5 (9%)
COPD, chronic obstructive pulmonary disease.
Table 2. Patient characteristics during the study
HHD CHD
Employ [n (%working
ability±SD)]
28 (41.8±36.2%) 26 (35.0±35.8%)
Learned profession [n (%)]
Technical/farming 28 (48.3%) 21 (36.2%)
Home 9 (15.5%) 10 (17.2%)
Ofﬁce 19 (32.8%) 26 (44.8%)
Working as [n (%)]
Technical/farming 22 (37.9%) 12 (20.7%)
Home 17 (29.3%) 16 (27.6%)
Ofﬁce 17 (29.3%) 27 (46.6%)
Hepatitis B antigen-positive 2 (3.4%) 6 (10.3%)
Hypertension [n (%)] 45 (77.6%) 51 (87.9%)
Mean duration of
hypertension±SD (years)
13.7±10.0 11.5±11.5
Transplanted during
study time (n)
28 31
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laparatomies (Table 3). Furthermore, there was a
tendency for more sigmoidectomies and appendec-
tomies in the CHD patient population. CHD patients
had more vascular problems, i.e. complications of
peripheral arterial disease, angina and myocardial
infarction. The proportion of parathyroidectomized
patients was higher in the group of HHD patients
(Table 3). HHD patients were also more often operated
for carpal tunnel syndrome (Table 3).
About half of the patients from each group died
during the observation period (Table 4). The leading
causes of death in both populations were cardiovas-
cular diseases followed by infections and cerebrovas-
cular insults in the CHD patients. Two patients of the
HHD group died of air embolism and another two
discontinued dialysis treatment. In 9% of cases, the
cause of death was not speciﬁed.
Survival time was signiﬁcantly longer in HHD as
compared with CHD. Five, 10 and 20 year survival was
93 (n¼ 55 patients at risk), 72 (41) and 34% (11) with
HHD and 64 (38), 48 (26) and 23% (4) with CHD,
respectively. Predictors of mortality identiﬁed by a
multivariate Cox proportional hazard model in
the population studied were age at onset of dialysis
(P<0.001), year of onset (P<0.001), Khan comorbid-
ity index (P<0.05) and treatment method (P<0.05).
The survival difference for treatment methods persisted
after adjustment for the other predictors of mortality.
The main cause of death was from cardiovascular
disease in both groups (25.9% for HHD and 22.4% for
CHD patients). HHD patients were signiﬁcantly less
hospitalized (6.3 vs 10.5 times per patient) and tended
to have fewer operations (6.4 vs 8.8 per patient) as
compared with the CHD patients.
If stratiﬁed for primary renal disease, there were
signiﬁcant differences concerning survival (log-rank
test: P<0.003), with patients having glomerulonephri-
tis living the shortest time (median survival: 8.4 years)
and those with interstitial nephropathy the longest
(median survival: 16.7 years). Patients with ADPKD
had a median survival time of 12.9 years and those with
renal vascular disease 11 years.
Discussion
From 1970 to 1995, a total of 103 patients started HHD
therapy in our centre. Fifty-eight of these patients could
be matched with patients that were concomitantly
treated in the dialysis facility according to time of
dialysis onset, age, gender and primary renal disease.
Survival analysis revealed a beneﬁt of HHD as
compared with CHD with respect to 5, 10 and 20
year survival rates. These ﬁndings were conﬁrmed by
the use of a stepwise multivariate Cox proportional
hazard model, where dialysis modality emerged as
the second most important mortality predictor after
patient age.
The ﬁndings of our study are well in accordance with
earlier reports of a survival beneﬁt of patients treated
by HHD [7–9,11]. Using a Cox proportional hazards
model and a national random sample of patients
starting ESRD treatment in 1986 and 1987, adjusted
for age, race, sex, diabetes as cause of renal disease and
comorbid factors present before onset or ESRD,
Woods et al. [8] reported a relative mortality risk of
0.58 for patients treated with HHD as compared with
CHD. The authors speculated that the observed
survival beneﬁt of HHD was due to an increased
compliance with medication, diet and dialysis prescrip-
tion. They could not exclude a selection bias with
respect to HHD patients having less severe abnormal-
ities in coronary artery, cerebral and peripheral
vascular disease and other unmeasured comorbid
conditions. Reported survival data from the major
HHD studies are summarized in Table 5. The rather
low patient survival of the only unselected HHD
population [5] hints at the importance of patient
selection on reported survival rates.
A randomized, controlled trial to compare HHD
with CHD is impossible for obvious reasons.
Patients cannot be randomized to HHD treatment, as
it requires the capability as well as the willingness of the
patient to participate. We focused on a strict match
of our HHD patients to the centre population,
considering sex, age (±5 years), year of haemodialysis
onset (±2 years), renal diagnosis (i.e. glomerulone-
phritis, pyelonephritis, analgesic nephropathy,
ADPKD, renal vascular disease and unknown).
Hence, the two studied populations were comparable
with respect to the mentioned criteria. Furthermore,
the comorbidity index [10] was comparable in both
populations.
Due to the strict matching process, for only 50% of
the HHD patients was a suitable match found in the
CHD population. Furthermore, neither the selected
HHD patients nor their matched patients from the
dialysis centre were any longer representative of their
corresponding population. The main reason for the
small number of patients that could be matched was the
strategy of our institution to consider pre-emptive
transplantation, HHD, self-care dialysis or CAPD
rather than passive CHD as a preferred choice for
young patients. Despite the fact that one of the HHD
patients was diabetic, no diabetic patient was found
Table 4. Mortality during dialysis
HHD CHD
Total number of deaths
during the study
29 (50%) 34 (58.6%)
Causes of death
Cardiovascular disease 14 (24.1%) 12 (20.7%)
Malignant disease 1 (1.7%) 4 (6.9%)
Infection 1 (1.7%) 6 (10.3%)
Gastrointestinal haemorrhage 0 (0%) 1 (1.7%)
Cerebral insult 0 (0%) 4 (6.9%)
Air embolism 2 (3.4%) 0 (0%)
Suicide 1 (1.7%) 1 (1.7%)
Dialysis 2 (3.4%) 0 (0%)
Other 3 (5.2%) 2 (3.4%)
Unknown 5 (8.6%) 4 (6.9%)
Mean follow-up±SD (years) 10.5±5.4 7.4±5.7
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as a match in the passive CHD population as self-care
dialysis patients were excluded.
HHD requires the help of a partner. Active patients
lacking a steady partnership are therefore not trained
for HHD, but are trained for an alternative active
dialysis method, i.e. peritoneal dialysis or self-care
haemodialysis. It is therefore not astonishing that more
married persons were found in the group of HHD
patients. A certain impact of this inhomogeneity on
patient mortality cannot be excluded, especially since
married people have been reported to have a longer
survival time.
Two-thirds of the studied patients were male. While
female patients are not per se underrepresented in the
population with active dialysis treatment (i.e. self-care
haemodialysis and peritoneal dialysis), a certain
disadvantage of female patients is observed as soon
as they require the help of their partner. The same
phenomenon can be observed for the gender distribu-
tion of nursing homes.
The observed difference in the type of occupation
between HHD and CHD in our study was not
surprising. HHD requires some manual skills from
the patients and, therefore, patients used to manual
work are easier convinced to do the dialysis treatment
themselves than white-collar workers. Furthermore,
farmers living in remote areas gain more time by HHD
as compared with patients living in a city close to a
dialysis facility.
While the observed overall survival was different
between HHD and CHD patients, there was no striking
difference with respect to the cause of death, with
cardiovascular disease being the major reason for dying
(Figure 1). This corresponds well to some published
data [12], while it is in discordance with others [13]. The
additional number of deaths observed in the CHD
patients occurred mainly during the initial month of
dialysis therapy and, therefore, we cannot postulate a
sustained survival advantage of HHD. It is not possible
to exclude a higher initial degree of comorbidity in
the CHD patients. Furthermore, patients originally
planned for future treatment at home who died before
or during the HHD training in the hospital were not
counted as HHD patients.
CHD patients tended to die more frequently from
malignancies, strokes and infections. However, it is
likely that in the HHD population, where more people
died at home as compared with the centre dialysis
patients, death from cardiac disease was more often
declared by the family practitioner as compared with
death declarations from the treating nephrologist being
fully aware of all concomitant diagnoses of the patient.
Two patients of the HHD group died of air embolism.
Table 5. HHD survival data as reported from the literature
Authors Observation
period
Number of
patients
Mean age
(years)
Survival (%)
1 Year 2 Years 3 Years 4 Years 5 Years 10 Years 15 Years 20 Years
Moorhead et al. [21] 1964–1970 89 – 99 93 91 86 – – – –
Roberts [22] 1967–1973 981 40 87 74 62 54 52 – – –
Delano [23] 1969–1996a 206 40 Mean survival: 6.4±6.4 years
Mailloux et al. [9] 1970–1993 74 44 – – – – 87 60 47 35
McGregor et al. [5] 1970–1979 92b 42 – 83 – – 57 – – –
1980–1989 127b 46 – 80 – – 56 – – –
1990–1997 115b 50 – 88 – – 75 – – –
Weller et al. [24] 1974–1978 261c 43d 86 75
Arkouche et al. [25] 1974–1997 552 31–53 – – – – 90 77 62 45
Hellerstedt et al. [26] 1978–1983 148 54 94 86 75 64 64 – – –
Grant et al. [11] 1982–1988 139 39 – – – – 71 – – –
aPublication year (end of observation period not given).
bUnselected HHD population (no CHD available).
cIncluding 29 patients treated with peritoneal dialysis.
dEstimated value.
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Fig. 1. Proportion of the matched patients surviving on HHD
(solid line) or CHD (dashed line) during the observation period.
The dotted line represents the survival of the 45 HHD patients who
could not be matched. The observed survival times of censored
patients are marked ‘þ’.
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This is a well-known danger of HHD that has been
described previously [14].
Patients dialysed in the centre were hospitalized more
often than HHD patients. This can be explained easily
for dialysis-related problems, since centre patients are
already dialysed in the hospital and see their physician
thrice weekly as compared with about every 6 weeks
for stable home dialysis patients. However, higher
frequencies for hospitalizations related to abdominal
problems as well as the number of laparatomies were
also higher in CHD – a circumstance with no obvious
explanation.
More parathyroidectomies and operations for carpal
tunnel syndrome were done in the HHD patients.
One might speculate that calcium and phosphate levels
were less rigorously controlled at home, possibly due
to compliance problems. Carpal tunnel syndrome in
dialysis patients has been associated with the type of
membrane [15] used for dialysis as well as the quality of
dialysate [16]. While we used the same dialysis ﬁlters at
home as in the centre (cuprophane before 1989 and,
exclusively, biocompatible membranes in recent years)
we cannot exclude the possibility of an inferior water
treatment at home, at least during the early years of
HHD. Furthermore, the differences encountered with
respect to carpal tunnel syndrome might also be
attributable to work-related factors [17].
Efﬁciency of dialysis was rather low as compared
with today’s standards (urea reduction rate 63 and
61%, respectively). The mean weekly dialysis treatment
time of <12 h is given mainly by the fact that several
patients were treated only twice a week. Patients were
treated differently in the past; however, our HHD
patients had conventional treatment schedules during
all eras, i.e. comparable to the patients treated in the
centre.
The observed decrease of patients starting HHD has
been attributed partly to the increased frequency of
transplantation in the young and selected population of
HHD patients. In our study, both patient groups were
transplanted with the same frequency invalidating the
argument that patients are either treated at home or
transplanted.
Except for Australia and New Zealand [4,5], the
number of HHD patients has been declining steadily
over the last decades. Elder and sicker patients, greater
mobility of patients and better distribution of dialysis
centres have all contributed to the decline in the
number of home dialysis patients. Furthermore, reim-
bursement policies often disadvantage the physician
and their patients, which themselves tend to prefer the
‘real medicine’ delivered at a dialysis centre [2].
HHD may become more attractive again with
the emergence of new therapy schedules, such as
daily haemodialysis and/or overnight haemodialysis.
Reports about dialysis patients treated with such
treatment schedules are encouraging with respect
to patient morbidity [18,19] and/or mortality [20].
However, investigations that focus on the separation of
the ‘home effect’ from a possible advantage of the
treatment modality per se are needed, especially if such
modalities are accompanied by an increased need for
ﬁnancial and/or human resources.
Considerable patient selection occurs during the
decision process about which renal replacement ther-
apy to choose. Patients on HHD are a selection of
healthier and younger patients with better rehabili-
tation proﬁle [8]. As HHD requires a considerable
commitment of time and effort by the patients and their
family, one could speculate that this population is
more compliant with medication, diet and dialysis
prescription, hence achieving a higher dose of dialysis
(Kt/V) [8]. Even if attributing the observed survival
beneﬁt of HHD treatment to persistent problems with
matching the two populations, we found no negative
effect of HHD on any of the studied parameters. This
ﬁnding together with possible advantages for the
patients treated at home in combination with a
ﬁnancial proﬁt for the society should be reasons
enough to continue convincing and training patients
for HHD.
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